NORTH KARGAR AVE., SHARIATI HOSPITAL, TEHRAN UNIVERSITY OF MEDICAL SCIENCES, TEHRAN, IRAN• PHONE: 0098-912-7997-219 • E–MAIL PGERAMIFAR@TUMS.AC.IR

CURRICULUM VITAE FOR PARHAM GERAMIFAR, PHD

POSITIONS

ThermoOncology Knowledge Base Co.
2022/04 - Now CEO

Tehran University of Medical Sciences, Tehran, Iran
2015/07 - Now Assistant Professor, Departments of Medical Physics and Nuclear Medicine

Shariati Hospital, Tehran, Iran
2010/02 - Now Medical Imaging Physicist, Medical Radiation Protection Officer (PET/CT, SPECT/CT, Cyclotron)

EDUCATION AND BOARD CERTIFICATION

2008 – 2013 Amirkabir University of Technology (Tehran Polytechnic)
Ph.D. Degree: *Medical Radiation Engineering*

- PET Respiratory Artifact Quantification/Correction using 4DXCAT Phantom
- Thesis: "Quantification and Reduction of Respiration Motion Induced Artifacts in CTAC Positron Emission Tomography (PET) Using Virtual Average CT"

2005 – 2008 Amirkabir University of Technology (Tehran Polytechnic)
M.Sc. Degree: *Medical Radiation Engineering*

- Investigation of Time-of-Flight (TOF) Benefits in PET Scanner using GATE
- Thesis: "Evaluation of Time of Flight Benefits for Fully 3D PET Using Monte Carlo Simulation"

2000 - 2005 Ferdowsi University of Mashhad
B.Sc. Degree: *Electric and Electronic Engineering*

- Thesis: "LabView Communication with a Microcontroller Over an USB Port"

RESEARCH, TEACHING, AND CLINICAL SERVICE

1. **Research Activities** Interdisciplinary training/research towards dynamic acquisition, quantitative medical image analysis and dosimetry for tomographic imaging modalities (PET, SPECT) including Monte Carlo simulations and phantom experimental studies. Active areas include:
    a. Dynamic and Dual time Point (DTP) PET/CT imaging
    b. Texture analysis (radiomics) in PET imaging for enhanced diagnosis, prognosis and treatment response assessment (lymphoma cancer)
    c. Respiratory motion compensation in PET imaging
    d. Monte Carlo simulation using GATE and mathematical anthropomorphic models

2. **PET/CT, SPECT/CT Medical Imaging Physicist**
    a. Supervision of various quality assurance and compliance efforts
    b. Supervision of regular set-up, calibration and normalization efforts, including amendment of procedures & sources
    c. Regular training, interaction and input into ongoing and upcoming imaging protocols, including upper/lower dose limitations, transmission scanning, interrupted scans, etc.
    d. Collaboration with staff and scientists at radiochemistry labs for assessment and enrollment of new PET and SPECT imaging radiotracers, protocols and applications

3. **Teaching:**
    a. **Course Lecturer** (2013-): "Nuclear Medicine Physics", Department of Nuclear Medicine, Tehran University of Medical Sciences.
    b. **Course Lecturer** (2015-): "Quantitative Analysis in Nuclear Medicine" Departments of Nuclear Medicine and Medical Physics, Tehran University of Medical Sciences.
    c. **Medical Physics/Imaging Lecturer** (2013-): for Nuclear Medicine Residents and PhD/MSc students of Medical Physics, Medical Radiation Engineering, and Radiology at the Department of Nuclear Medicine, Tehran University of Medical Sciences.

PUBLICATION

Summary: 1 book (9 chapters), > 100 publications (Journal Publications + Conference Proceeding Papers/Abstracts)
h-index: 20
Citations: >1200

Google scholar: https://scholar.google.com/citations?hl=en&user=SjfZMFQAAAAJ

Linkedin: https://www.linkedin.com/in/parham-geramifar-35147b222/

Book

Positron Emission Tomography: Physics, Instrumentation, Scanners and New Horizons
Authors: M.R. Ay and P. Geramifar
Publisher: Royan Pazhoh
Tehran, Iran, ISBN-13: 9786007108543

Journal Papers

1. M Peer-Firozjaei, MA Tajik-Mansoury, **P Geramifar**, R Ghorbani, S Zarifi, Optimized cocktail of 90Y/177Lu for radionuclide therapy of neuroendocrine tumors of various sizes: a simulation study, Nuclear Medicine Communications, 2022, 43 (6), 646-655.

2. NA Olia, A Kamali-Asl, SH Tabrizi, **P Geramifar**, P Sheikhzadeh, Deep learning-based noise reduction in low dose SPECT Myocardial Perfusion Imaging: Quantitative assessment and clinical performance, Eur J Nucl Med Mol Imaging, 2022, 49, 1508–1522.

3. Z Falahatpour, **P Geramifar**, SR Mahdavi, A Nikoofar, Potential Advantages Of Fdg-Pet Radiomics Features In Non-Small Cell Lung Cancer: Delineation Of Tumor And Intratumoral Heterogeneity, Physica Medica: European Journal of Medical Physics, 2022, 94, S110.

4. A Alikhassi, AF Esfahani, **P Geramifar**, A Bitarafan-Rajabi, Metabolic and Texture Features of PET/CT Scan to Predict Response in Patients with Locally Advanced Rectal Cancer Treated by Concurrent Neoadjuvant Chemoradiotherapy, Research Square; 2022.

5. Z Falahatpour, **P Geramifar**, SR Mahdavi, H Abdollahi, Y Salimi, Potential advantages of FDG-PET radiomic feature map for target volume delineation in lung cancer radiotherapy, Journal of Applied Clinical Medical Physics, 2022, e13696.

6. S Izadi, I Shiri, C Uribe, **P Geramifar**, H Zaidi, A Rahmim, G Hamarneh, Enhanced Direct Joint Attenuation and Scatter Correction of Whole-Body PET Images via Context-Aware Deep Networks, medRxiv, 2022.05.26.22275662;

7. I Shiri, Y Salimi, M Pakbin, G Hajianfar, AH Avval, A Sanaat, S Mostafaei, **P Geramifar,** et. Al., COVID-19 Prognostic Modeling Using CT Radiomic Features and Machine Learning Algorithms: Analysis of a Multi-Institutional Dataset of 14,339 Patients, 2022, Volume 145, 105467.

8. S Barati, M Enferadi, S Sarkar, **P Geramifar,** The effect of magnetic field strength on the positron range and projected annihilation artifact in integrated PET/MR systems: a GATE Monte Carlo study, Medical Physics, 2021 , 48 (12), 7712-7724.

9. T Almasi, N Gholipour, M Akhlaghi, A Mokhtari Kheirabadi, SM Mazidi, **P Geramifar,** et.al, Development of Ga-68 radiolabeled DOTA functionalized and acetylated PAMAM dendrimer-coated iron oxide nanoparticles as PET/MR dual-modal imaging agent, International Journal of Polymeric Materials and Polymeric Biomaterials, 2021, 70:15, 1077-1089

10. S Yavari, **P Geramifar,** M Fallahpoor, V Changizi, M Gholami, A Meysamie, The effect of lithium on radioiodine thyroid tissue ablation, International Journal of Radiation Research, 2021, 19 (4), 1045-1048

11. B Moasses-Ghafari, B Fallahi, AF Esfehani, M Eftekhari, K Rahmani, **P Geramifar,** Effect of Diet on Physiologic Bowel 18F-FDG Uptake, Journal of Nuclear Medicine Technology, 2021, 49 (3), 241-245

12. K Bamneshin, SR Mahdavi, A Bitarafan-Rajabi, **P Geramifar**, P Hejazi, Breathing-induced Errors in Quantification and Description of Dominant Intra-Prostatic Lesions (Dils) in PET Images: A Simulation Study by Means of The 4D NCAT Phantom, Journal of Biomedical Physics and Engineering, 2021.

13. K Bamneshin, S Rabi Mahdavi, A Bitarafan-Rajabi, **P Geramifar**, P Hejazi, Evaluation of Dose-Painting in the Dominant Intraprostatic Lesions by Radiobiological Parameters using 68Ga-PSMA PET/CT, Journal of Biomedical Physics and Engineering, 2021.

14. M Peer-Firozjaei, MA Tajik-Mansoury, **P Geramifar**, AA Parach, S Zarifi , Implementation of dose point kernel (DPK) for dose optimization of 177Lu/90Y cocktail radionuclides in internal dosimetry, 2021, Applied Radiation and Isotopes, 173, 109673

15. H Vosoughi, M Hajizadeh, F Emami, M Momennezhad, **P Geramifar,** PET NEMA IQ Phantom dataset: image reconstruction settings for quantitative PET imaging, Data in Brief, 2021, 37, 107231

16. I Shiri, M Sorouri, **P Geramifar**, M Nazari, M Abdollahi, Y Salimi, Machine learning-based prognostic modeling using clinical data and quantitative radiomic features from chest CT images in COVID-19 patients, Computers in biology and medicine 2021, 132, 104304

17. I Shiri, Y Salimi, A Saberi, M Pakbin, G Hajianfar, AH Avval, A Sanaat, **P Geramifar,** et. Al., Diagnosis of COVID-19 Using CT image Radiomics Features: A Comprehensive Machine Learning Study Involving 26,307 Patients, medRxiv 2021.12.07.21267367

18. A Emami, H Ghadiri, P Ghafarian, P Geramifar, MR Ay, Performance evaluation of developed dedicated breast PET scanner and improvement of the spatial resolution by wobbling: a Monte Carlo study, Japanese journal of radiology 38 (8), 790-799

19. Tekie FSM, Hajiramezanali M, **Geramifar P**, Raoufi M, Dinarvand R, Soleimani M, et al. Controlling evolution of protein corona: a prosperous approach to improve chitosan-based nanoparticle biodistribution and half-life. Sci Rep. 2020;10(1):9664.

20. Shiri I, Hajianfar G, Sohrabi A, Abdollahi H, S PS, **Geramifar P**, et al. Repeatability of radiomic features in magnetic resonance imaging of glioblastoma: Test-retest and image registration analyses. Med Phys. 2020;47(9):4265-80.

21. Shiri I, Arabi H, **Geramifar P**, Hajianfar G, Ghafarian P, Rahmim A, et al. Deep-JASC: joint attenuation and scatter correction in whole-body (18)F-FDG PET using a deep residual network. Eur J Nucl Med Mol Imaging. 2020;47(11):2533-48.

22. Samimi R, Kamali-Asl A, **Geramifar P**, van den Hoff J, Rahmim A. Short-duration dynamic FDG PET imaging: Optimization and clinical application. Phys Med. 2020;80:193-200.

23. Pirooznia N, Abdi K, Beiki D, Emami F, Arab SS, Sabzevari O, et al. Radiosynthesis, Biological Evaluation, and Preclinical Study of a (68)Ga-Labeled Cyclic RGD Peptide as an Early Diagnostic Agent for Overexpressed alpha v beta 3 Integrin Receptors in Non-Small-Cell Lung Cancer. Contrast Media Mol Imaging. 2020;2020:8421657.

24. Mosayebnia M, Hajimahdi Z, Beiki D, Rezaeianpour M, Hajiramezanali M, **Geramifar P**, et al. Design, synthesis, radiolabeling and biological evaluation

of new urea-based peptides targeting prostate specific membrane antigen. Bioorg Chem. 2020;99:103743.

25. Maeng J, Chakraborty B, Geramifard N, Kang T, Rihani RT, Joshi-Imre A, et al. High-charge-capacity sputtered iridium oxide neural stimulation electrodes deposited using water vapor as a reactive plasma constituent. J Biomed Mater Res B Appl Biomater. 2020;108(3):880-91.

26. Jokar S, Behnammanesh H, Erfani M, Sharifzadeh M, Gholami M, Sabzevari O, et al. Synthesis, biological evaluation and preclinical study of a novel (99m)Tc-peptide: A targeting probe of amyloid-beta plaques as a possible diagnostic agent for Alzheimer's disease. Bioorg Chem. 2020;99:103857.

27. Hariri Tabrizi S, Ramezani M, Feghhi SAH, **Geramifar P**. In vitro evaluation of an iodine radionuclide dosimeter (IRD) for continuous patient monitoring. Med Biol Eng Comput. 2020;58(4):763-9.

28. Gholipour N, Akhlaghi M, Mokhtari Kheirabadi A, **Geramifar P**, Beiki D. Development of Ga-68 labeled, biotinylated thiosemicarbazone dextran-coated iron oxide nanoparticles as multimodal PET/MRI probe. Int J Biol Macromol. 2020;148:932-41.

29. Emami A, Ghadiri H, Ghafarian P, **Geramifar P**, Ay MR. Performance evaluation of developed dedicated breast PET scanner and improvement of the spatial resolution by wobbling: a Monte Carlo study. Jpn J Radiol. 2020;38(8):790-9.

30. Behnammanesh H, Jokar S, Erfani M, **Geramifar P**, Sabzevari O, Amini M, et al. Design, preparation and biological evaluation of a (177)Lu-labeled somatostatin receptor antagonist for targeted therapy of neuroendocrine tumors. Bioorg Chem. 2020;94:103381.

31. Behnammanesh H, Erfani M, Hajiramezanali M, Jokar S, **Geramifar P**, Sabzevari O, et al. Preclinical study of a new (177)Lu-labeled somatostatin receptor antagonist in HT-29 human colorectal cancer cells. Asia Ocean J Nucl Med Biol. 2020;8(2):109-15.

32. Tadesse GF, **Geramifar P**, Tegaw EM, Ay MR. Techniques for generating attenuation map using cardiac SPECT emission data only: a systematic review. Ann Nucl Med. 2019;33(1):1-13.

33. Shiri I, Ghafarian P, **Geramifar P**, Leung KH, Ghelichoghli M, Oveisi M, et al. Direct attenuation correction of brain PET images using only emission data via a deep convolutional encoder-decoder (Deep-DAC). Eur Radiol. 2019;29(12):6867-79.

34. Shayesteh SP, Alikhassi A, Fard Esfahani A, Miraie M, **Geramifar P**, Bitarafan-Rajabi A, et al. Neo-adjuvant chemoradiotherapy response prediction using MRI based ensemble learning method in rectal cancer patients. Phys Med. 2019;62:111-9.

35. Khoshbakht S, Beiki D, **Geramifar P**, Kobarfard F, Sabzevari O, Amini M, et al. Design, Synthesis, Radiolabeling, and Biologic Evaluation of Three (18)F-FDG-Radiolabeled Targeting Peptides for the Imaging of Apoptosis. Cancer Biother Radiopharm. 2019;34(5):271-9.

36. Hajiramezanali M, Atyabi F, Mosayebnia M, Akhlaghi M, **Geramifar P**, Jalilian AR, et al. (68)Ga-radiolabeled bombesin-conjugated to trimethyl chitosan-coated superparamagnetic nanoparticles for molecular imaging: preparation, characterization and biological evaluation. Int J Nanomedicine. 2019;14:2591-605.

37. Fallahi B, Manafi-Farid R, Eftekhari M, Fard-Esfahani A, Emami-Ardekani A, **Geramifar P**, et al. Diagnostic efficiency of (68)Ga-DOTATATE PET/CT as compared to (99m)Tc-Octreotide SPECT/CT andonventional orphologic odalities in neuroendocrine tumors. Asia Ocean J Nucl Med Biol. 2019;7(2):129-40.

38. Amirrashedi M, Sarkar S, Ghafarian P, Hashemi Shahraki R, **Geramifar P**, Zaidi H, et al. NEMA NU-4 2008 performance evaluation of Xtrim-PET: A prototype SiPM-based preclinical scanner. Med Phys. 2019;46(11):4816-25.

39. Rezaeianpour S, Mosayebnia M, Moghimi A, Amidi S, **Geramifar P**, Kobarfard F, et al. [(18)F]FDG-Labeled CGPRPPC Peptide Serving as a Small Thrombotic Lesions Probe, Including a Comparison with [(99m)Tc]-Labeled Form. Cancer Biother Radiopharm. 2018;33(10):438-44.

40. Ebrahimi M, Kardan MR, Changizi V, Pooya SMH, **Geramifar P**. Prediction of dose to the relatives of patients treated with radioiodine-131 using neural networks. J Radiol Prot. 2018;38(1):422-33.

41. Almasi A, Shahhosseini S, Haeri A, Daha FJ, **Geramifar P**, Dadashzadeh S. Radiolabeling of Preformed Niosomes with [(99m)Tc]: In Vitro Stability, Biodistribution, and In Vivo Performance. AAPS PharmSciTech. 2018;19(8):3859-70.

42. Shiri I, Rahmim A, Ghaffarian P, **Geramifar P**, Abdollahi H, Bitarafan-Rajabi A. The impact of image reconstruction settings on 18F-FDG PET radiomic features: multi-scanner phantom and patient studies. Eur Radiol. 2017;27(11):4498-509.

43. M Khazaee, A Kamali-Asl, **P Geramifar**, A Rahmim. **(2017)**, Low-dose 90Y PET/CT imaging optimized for lesion detectability and quantitative accuracy: a phantom study to assess the feasibility of pretherapy imaging to plan the therapeutic dose, Nuclear medicine communications, 38 (11), 985-997.

44. AR Jalilian, A Lahooti, **P Geramifar**, D Beiki, H Yousefnia, A Rabiee, M Mazidi, SF Mirshojaei, S Maus. **(2017)**, Preclinical evaluation of 68Ga-MAA from commercial available 99mTc-MAA kit, Iranian Journal of Pharmaceutical Research, 16(4), 1415-1423.

45. F Mottaghitalab, M Kiani, M Farokhi, SC Kundu, RL Reis, M Gholami, H Bardania, R Dinarvand, **P Geramifar**, D Beiki, F Atyabi. **(2017)**, Targeted Delivery System Based on Gemcitabine-Loaded Silk Fibroin Nanoparticles for Lung Cancer Therapy, ACS applied materials & interfaces, 9 (37), 31600-31611.

46. P Sheikhzadeh, H Sabet, H Ghadiri, **P Geramifar**, H Mahani, P Ghafarian, MR Ay. **(2017),** Development and validation of an accurate GATE model for NeuroPET scanner, Physica Medica: European Journal of Medical Physics, 40, 59-65.

47. M Soufi, A Kamali-Asl, **P Geramifar**, A Rahmim. **(2017)**, A Novel Framework for Automated Segmentation and Labeling of Homogeneous Versus Heterogeneous Lung Tumors in [18F] FDG-PET Imaging, Molecular Imaging and Biology, 19 (3), 456-458.

48. M Sharifi, H Yousefnia, A Bahrami-Samani, AR Jalilian, S Zolghadri, B Alirezapour, **P Geramifar**, S Maus, D Beiki. **(2017)**, Optimized production, quality control, biological evaluation and PET/CT imaging of 68Ga-PSMA-617 in breast adenocarcinoma model, Radiochimica Acta, 105 (5), 399-407.

49. S Rezaeianpour, AH Bozorgi, A Moghimi, A Almasi, S Balalaie, S Ramezanpour, S Nasoohi, SM Mazidi, **P Geramifar**, A Bitarafan-Rajabi, S Shahhosseini. **(2017)**, Synthesis and Biological Evaluation of Cyclic [99mTc]-HYNIC-CGPRPPC as a Fibrin-Binding Peptide for Molecular Imaging of Thrombosis and Its Comparison with [99mTc]-HYNIC-GPRPP, Mol Imaging Biol, 19 (2), 256-264.

50. N Gholipour, M Akhlaghi, A Mokhtari Kheirabadi, D Beiki, **P Geramifar**, H Yousefnia, M Mazidi. **(2017)**, Chelator-free radiolabeling of dextran with 68 Ga for PET studies, Journal of Radioanalytical and Nuclear Chemistry, 311 (3), 1811-1817.

51. B Fallahi, B Moasses-Ghafari, A Fard-Esfahani, **P Geramifar**, D Beiki, A Emami-Ardekani, M Eftekhari. **(2017)**, Factors influencing the pattern and

intensity of myocardial 18F-FDG uptake in oncologic PET-CT imaging, Iranian Journal of Nuclear Medicine, 25 (1), 52-61.

52. S Shanehsazzadeh, AR Jalilian, A Lahooti, **P Geramifar**, D Beiki, H Yousefnia, A Rabiee, M Mazidi, SF Mirshojaei, S Maus. **(2017)**, Preclinical Evaluation of 68Ga-MAA from Commercial Available 99mTc-MAA Kit, Iranian Journal of Pharmaceutical Research, 16 (4), 1415-1423.

53. B Fallahi, A Fard-Esfahani, A Emami-Ardekani, S Sahari, D Beiki, A Hassanzadeh-Rad, S M Abedi, **P Geramifar**, M Eftekhari. **(2017)**, How to manage patients with undetectable thyroglobulin but thyroid residue after radioiodine ablative therapy in differentiated thyroid carcinoma, retreatment or observation?, Iranian Journal of Nuclear Medicine, 25(1), 51-59.

54. S Izadyar, S Farzanehfar, MR Amjad, M Abbasi, A Emami Ardekani, B Fallahi, A Fard Esfehani, J Esmaeli, F Akhzari, **P Geramifar**. **(2016)**, Association of Ischemic Heart Disease Assessed by Radionuclide Myocardial Perfusion Imaging with Bone Mineral Density Measurements by Dual-Energy X-Ray Absorptiometry and Serum Vitamin D Deficiency, Iranian Journal of Radiology, 14 (2).

55. A Lahooti, S Sarkar, H Saligheh Rad, A Gholami, S Nosrati, RN Muller, S Laurent, C Grüttner, **P Geramifar**, H Yousefnia, M Mazidi, S Shanehsazzadeh **(2107)**, PEGylated superparamagnetic iron oxide nanoparticles labeled with 68Ga as a PET/MRI contrast agent: a biodistribution study, Journal of Radioanalytical and Nuclear Chemistry, 311 (1), 769-774.

56. MK Moghadam, A Kamali-Asl, **P Geramifar**, H Zaidi. **(2016)**. Evaluating the Application of Tissue-Specific Dose Kernels Instead of Water Dose Kernels in Internal Dosimetry: A Monte Carlo Study, Cancer Biotherapy and Radiopharmaceuticals, 31 (10), 367-379.

57. M Sharifi, H Yousefnia, S Zolghadri, A Bahrami-Samani, M Naderi, AR Jalilian, **P Geramifar**, D Beiki. **(2016)**, Preparation and biodistribution assessment of 68Ga-DKFZ-PSMA-617 for PET prostate cancer imaging, Nuclear Science and Techniques, 27 (6), 142.

58. M Pashnehsaz, A Takavar, S Izadyar, SS Zakariaee, M Mahmoudi, R Paydar, **P Geramifar**. **(2016)**, Gastrointestinal Side Effects of the Radioiodine Therapy for the Patients with Differentiated Thyroid Carcinoma Two Days after Prescription, World J Nucl Med.15(3), 173–178.

59. AR Jalilian, D Beiki, A Hassanzadeh-Rad, A Eftekhari, **P Geramifar**, M Eftekhari. **(2016)**. Production and clinical applications of radiopharmaceuticals and medical radioisotopes in Iran. Seminars in nuclear medicine, 46(4), 340-358.

60. A Fard-Esfahani, M Marzban, A Emami-Ardekani, A Hassanzadeh-Rad, B Fallahi, D Beiki, **P Geramifar**, M Eftekhari **(2016)**.Spinal cord metastasis from testicular seminoma detected by F-18 FDG PET/CT study prior to neurological symptoms: An unusual presentation, Iranian Journal of Nuclear Medicine, 24(2), 147-149.

61. B Fallahi, A Esmaeili, D Beiki, Sh Oveisgharan, H Noorollahi-Moghaddam, M Erfani, A Tafakhori, M Rohani, A Fard-Esfahani, A Emami-Ardekani, **P Geramifar**, M Eftekhari. **(2016)**. Evaluation of 99mTc-TRODAT-1 SPECT in the diagnosis of Parkinson's disease versus other progressive movement disorders. Annals of nuclear medicine, 30 (2), 153-162

62. Soufi M, Kamali-Asl A, **Geramifar P**, Abdoli M, Rahmim A. **(2016)**. Combined fuzzy logic and random walker algorithm for PET image tumor delineation. Nuclear Medicine Communications, 37(2), 171-181.

63. S Khoshbakht, D Beiki, **P Geramifar**, F Kobarfard, O Sabzevari, M Amini, F Mehrnejad, S Shahhosseinig. **(2016)**. Synthesis, Radiolabeling, and Biological Evaluation of Peptide LIKKPF Functionalized with HYNIC as Apoptosis Imaging Agent. Iran J Pharm Res, 15(2), 415–424.

64. S Khoshbakht, D Beiki, **P Geramifar**, F Kobarfard, O Sabzevari, M Amini, S Shahhosseini. **(2016)**. 18FDG-labeled LIKKPF: a PET tracer for apoptosis imaging. J Radioanal Nucl Chem.310 (1), 413–421.

65. Aghanejad A, Jalilian AR, Maus S, Yousefnia H, **Geramifar P**, Beiki D. **(2016)**. Optimized production and quality control of 68Ga-DOTATATE. Iran J Nucl Med, 24 (1), 29-36.

66. S Shanehsazzadeh, A Lahooti, H Yousefnia, **P Geramifar**, AR Jalilian. **(2015)**. Comparison of estimated human dose of 68Ga-MAA with 99mTc-MAA based on rat data. Annals of Nuclear Medicine, 29 (8), 745-753.

67. Mirzaei, A., A. R. Jalilian, A. Badbarin, M. Mazidi, F. Mirshojaei, **P. Geramifar**, and D. Beiki. **(2015)**. Optimized Production and Quality Control of (68) Ga-EDTMP for Small Clinical Trials. Annals of nuclear medicine, 29(6), 506-11.

68. Jalilian, A. R., A. Mirzaei, A. Aghanejad, M. Mazidi, H. Yousefnia, G. Shabani, K. Ardaneh, **P. Geramifar**, and D. Beiki. **(2015)**. Preparation and Evaluation of 68ga-Ecc as a PET Renal Imaging Agent. Nuclear Medicine and Molecular Imaging, 49 (3), 208–216.

69. **Geramifar P.**, Zafarghandi M.S., Ghafarian P., Rahmim A., Ay M.R. **(2013)**. Respiratory-Induced Errors in Tumor Quantification and Delineation in CT Attenuation-Corrected PET Images: Effects of Tumor Size, Tumor Location,

and Respiratory Trace: A Simulation Study Using the 4D XCAT Phantom. Molecular Imaging and Biology,15(6), 655-65.

70. **Geramifar P.**, Ay M.R., Zafarghandi M.S., Sarkar S., Loudos G., Rahmim A. **(2011)**. Investigation of time-of-flight benefits in an LYSO-based PET/CT scanner: A Monte Carlo study using GATE. Nuclear Instruments and Methods in Physics Research Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 641(1), 121-127.

71. Zeraatkar N., Ay M.R., Ghafarian P., Sarkar S., **Geramifar P.**, Rahmim A. **(2011)**. Monte Carlo-based evaluation of inter-crystal scatter and penetration in the PET subsystem of three GE Discovery PET/CT scanners. Nuclear Instruments and Methods in Physics Research Section A: Accelerators, Spectrometers, Detectors and Associated Equipment 659(1), 508-514.

72. **Geramifar P.**, Ay M.R., Zafarghandi M.S., Loudos G. **(2009)**. Performance Comparison of Four Commercial GE Discovery PET/CT Scanners: A Monte Carlo Study Using GATE. Iranian Journal of Nuclear Medicine, 17(2), 26-33.

Conference Proceedings Papers/Abstracts

Complete list of all works can be found at:
Google scholar page

Computer Skills

. Programming with C++

. GATE Monte Carlo Packages in NM/PET

PERSONAL AND CONTACT INFORMATION

Address: Parham Geramifar, PhD,

Shariati Hospital, North Kargar Ave.
1411713135, Tehran, Iran.

Phone: +98-21-88220363

Fax: +98-21- 88026905,

E-mail: pgeramifar@tums.ac.ir